WVE
Wave Life Sciences Ltd. (WVE) Economic Moat Analysis (2026)
Overall Score
Scale Pricing Power
Gross margin remains exceptionally high at 96.5%, indicating strong pricing power on the current product mix.
Revenue per share is still low at 0.32, so the business has not yet translated margin strength into meaningful scale.
Profitability Returns
TTM profitability remains deeply negative, with operating margin at -333.4% and net margin at -309.7%.
Returns on capital are still poor, with ROIC at -42.6% and ROE at -50.1%, showing no durable economic profit yet.
Balance Sheet Resilience
Liquidity is very strong, with a current ratio of 10.0 and cash ratio of 7.2.
Leverage remains modest, with debt-to-equity at 0.10 and debt-to-assets at 7.8%, but solvency is still pressured by negative earnings and cash flow.
Cash Generation Quality
Operating cash flow and free cash flow remain negative, with FCF yield at -17.5% and OCF yield at -36.3%.
Cash conversion is weak despite high income quality, as free cash flow to equity is still negative at -185.5 million.
Moat Durability Intangibles
There is no clear evidence of a durable moat from the current financials, as returns remain negative and the business is still loss-making.
R&D intensity is high at 302.0% of revenue, which may support future differentiation but has not yet produced durable economic returns.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Wave Life Sciences Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

